Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00UWY
|
|||
| Former ID |
DIB003536
|
|||
| Drug Name |
RT-001
|
|||
| Synonyms |
RT-001, Revance therapeutics; BoNTA protein (topical gel, hyperhidrosis), Revance
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acne vulgaris [ICD-11: ED80; ICD-10: L70.0; ICD-9: 706.1] | Phase 2 | [1] | |
| Friedreich's ataxia [ICD-11: 8A03.10; ICD-9: 334] | Phase 1/2 | [2] | ||
| Company |
Revance Therapeutics Inc
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C20H36O2
|
|||
| Canonical SMILES |
CCCCCC=CCC=CCCCCCCCC(=O)OCC
|
|||
| InChI |
1S/C20H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22-4-2/h8-9,11-12H,3-7,10,13-19H2,1-2H3/b9-8-,12-11-/i10D2
|
|||
| InChIKey |
FMMOOAYVCKXGMF-XMCVDNGOSA-N
|
|||
| CAS Number |
CAS 1404475-07-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Botulinum toxin A (Bact botA) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01124565) Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of Revance Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.